Scilex Holding Company

Scilex Holding Company is a pharmaceutical firm dedicated to the acquisition, development, and commercialization of non-opioid pain management products for both acute and chronic pain. The company's mission is to become a global leader in pain management, adhering to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products that enhance quality of life. Scilex Holding Company is headquartered in Palo Alto, California.

Its commercial product portfolio includes ZTlido® (lidocaine topical system) 1.8% for neuropathic pain associated with post-herpetic neuralgia, ELYXYB® (oral solution) for the acute treatment of migraine, and GLOPERBA® (liquid oral colchicine) for the prophylaxis of gout flares. The company also has a pipeline of product candidates, including SP-102 (SEMDEXA™) for lumbosacral radicular pain, SP-103 (lidocaine topical system) 5.4% for acute lower back pain and chronic neck pain, and SP-104 (low-dose naltrexone hydrochloride) for fibromyalgia.

In recent news, Scilex Holding Company announced a $20 million strategic investment in Quantum Scan Holdings, Inc. in January 2026. The company also declared a dividend of Dream Bowl Meme Coin I tokens to shareholders, with plans for listing on the Biconomy Exchange as early as June 23, 2026. Additionally, Scilex confirmed a dividend of Semnur Pharmaceuticals, Inc. common stock to its shareholders with a record date of June 1, 2026. Henry Ji serves as the Executive Chairman, Chief Executive Officer, and President. While Scilex Holding Company is majority-owned by Sorrento Therapeutics, Inc., it is not a debtor in Sorrento's ongoing Chapter 11 bankruptcy proceedings.